Literature DB >> 21850277

Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia.

Athena T Samaras1, Charles L Bennett.   

Abstract

Entities:  

Year:  2008        PMID: 21850277      PMCID: PMC3156058     

Source DB:  PubMed          Journal:  Am J Hematol Oncol        ISSN: 1939-6163


× No keyword cloud information.
  15 in total

1.  Breast cancer trial with erythropoietin terminated unexpectedly.

Authors:  Brian Leyland-Jones
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

2.  Erythropoietin, the FDA, and oncology.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

3.  Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.

Authors:  D H Henry; B J Brooks; D C Case; E Fishkin; R Jacobson; A M Keller; J Kugler; J Moore; R T Silver; A M Storniolo; R I Abels; D S Gordon; R Nelson; K Larholt; E Bryant; S Rudnick
Journal:  Cancer J Sci Am       Date:  1995 Nov-Dec

Review 4.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  J Bohlius; J Wilson; J Seidenfeld; M Piper; G Schwarzer; J Sandercock; S Trelle; O Weingart; S Bayliss; S Brunskill; B Djulbegovic; C L Benett; S Langensiepen; C Hyde; E Engert
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

Review 5.  Erythropoietin biology in cancer.

Authors:  Matthew E Hardee; Murat O Arcasoy; Kimberly L Blackwell; John P Kirkpatrick; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

6.  Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment.

Authors:  Kyriaki Mystakidou; Ourania Kalaidopoulou; Emmanuela Katsouda; Efi Parpa; Evangelia Kouskouni; Costas Chondros; Marinos L Tsiatas; Lambros Vlahos
Journal:  Anticancer Res       Date:  2005 Sep-Oct       Impact factor: 2.480

7.  Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer.

Authors:  H-G Strauss; G Haensgen; J Dunst; C R W Hayward; H-U Burger; A Scherhag; H Koelbl
Journal:  Int J Gynecol Cancer       Date:  2007-07-21       Impact factor: 3.437

8.  Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Authors:  Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

9.  Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.

Authors:  P M Wilkinson; M Antonopoulos; M Lahousen; M Lind; P Kosmidis
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

10.  Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.

Authors:  Matthew E Hardee; Yiting Cao; Ping Fu; Xiaohong Jiang; Yulin Zhao; Zahid N Rabbani; Zeljko Vujaskovic; Mark W Dewhirst; Murat O Arcasoy
Journal:  PLoS One       Date:  2007-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.